Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Human Resources Officer | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,650 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 11,650 · Balance 11,650 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.47 · Expires 2036-02-10 | Direct | 17,500 |
Reported balance
After 2026-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-11 · Grant · Acquired 17,500 · Balance 17,500 F3: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.
F3: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 20, 2025 02:43 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015317 · tm257103-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3 | $57.54 | $172.62 |
DisclosureSEC source: 0001104659-25-011676 · tm256299-2_4seq1.xml · nonDerivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,891 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 698 | $57.51 | $40,141.98 |
DisclosureSEC source: 0001104659-25-011676 · tm256299-2_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,894 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-011676 · tm256299-2_4seq1.xml · derivative · entry 4 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,343 Underlying: Common Stock · 2,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-011676 · tm256299-2_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 02:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 902 | $59.43 | $53,605.86 |
DisclosureSEC source: 0001104659-25-009282 · tm255457-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,248 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 02:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-009282 · tm255457-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 2,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 02:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-009282 · tm255457-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to buy) · Derivative | 4,688 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001104659-24-115867 · tm2427804-1_4seq1.xml · derivative · entry 6 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,062 Underlying: Common Stock · 4,688 shares Expires 2031-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 4,688 | $65.00 | $304,720.00 |
DisclosureSEC source: 0001104659-24-115867 · tm2427804-1_4seq1.xml · nonDerivative · entry 4 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,688 | $19.02 | $89,165.76 |
DisclosureSEC source: 0001104659-24-115867 · tm2427804-1_4seq1.xml · nonDerivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to buy) · Derivative | 4,687 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001104659-24-115867 · tm2427804-1_4seq1.xml · derivative · entry 5 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 4,687 shares Expires 2031-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 4,687 | $60.00 | $281,220.00 |
DisclosureSEC source: 0001104659-24-115867 · tm2427804-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,687 | $19.02 | $89,146.74 |
DisclosureSEC source: 0001104659-24-115867 · tm2427804-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to buy) · Derivative | 4,099 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001104659-24-098945 · tm2423816-3_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,437 Underlying: Common Stock · 4,099 shares Expires 2031-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 4,099 | $50.03 | $205,062.31 |
DisclosureSEC source: 0001104659-24-098945 · tm2423816-3_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.13. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,099 | $19.02 | $77,962.98 |
DisclosureSEC source: 0001104659-24-098945 · tm2423816-3_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to buy) · Derivative | 3,200 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001104659-24-094013 · tm2422915-3_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,536 Underlying: Common Stock · 3,200 shares Expires 2031-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,200 | $50.01 | $160,017.92 |
DisclosureSEC source: 0001104659-24-094013 · tm2422915-3_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,200 | $19.02 | $60,864.00 |
DisclosureSEC source: 0001104659-24-094013 · tm2422915-3_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to buy) · Derivative | 30,771 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001104659-24-089008 · tm2421587d1_4seq1.xml · derivative · entry 4 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,736 Underlying: Common Stock · 30,771 shares Expires 2031-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,104 | $45.62 | $95,988.90 |
DisclosureSEC source: 0001104659-24-089008 · tm2421587d1_4seq1.xml · nonDerivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $45.53 to $45.77. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 46,902 | $45.13 | $2,116,509.03 |
DisclosureSEC source: 0001104659-24-089008 · tm2421587d1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,604 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $44.53 to $45.51. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 30,771 | $19.02 | $585,264.42 |
DisclosureSEC source: 0001104659-24-089008 · tm2421587d1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 21:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,395 | $49.06 | $68,438.70 |
DisclosureSEC source: 0001104659-24-084016 · tm2420478-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,735 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 21:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-084016 · tm2420478-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of July 26, 2022, July 26, 2023, July 26, 2024 and July 26, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of July 26, 2022, July 26, 2023, July 26, 2024 and July 26, 2025. The restricted stock units have no expiration date. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 21:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-084016 · tm2420478-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 00:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 15,515 | $39.22 | $608,498.30 |
DisclosureSEC source: 0001104659-24-036310 · tm249308-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,005 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.07 to $39.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:01 UTC | RHYTHM PHARMACEUTICALS, INC. SRYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 40,200 | $0.00 Strike: $49.23 | $0.00 |
DisclosureSEC source: 0001104659-24-026158 · tm246920-4_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,200 Underlying: Common Stock · 40,200 shares Expires 2034-02-15 F4 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:01 UTC | RHYTHM PHARMACEUTICALS, INC. SRYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 13,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026158 · tm246920-4_4seq1.xml · derivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:01 UTC | RHYTHM PHARMACEUTICALS, INC. SRYTM · Entity 3693 | GrantCommon Stock | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026158 · tm246920-4_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,520 F1 · shares: The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 01:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 696 | $51.38 | $35,760.48 |
DisclosureSEC source: 0001104659-24-022536 · tm246165-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,770 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022536 · tm246165-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,687 Underlying: Common Stock · 2,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-022536 · tm246165-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010796 · tm245251-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,950 Underlying: Common Stock · 2,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 946 | $45.06 | $42,626.76 |
DisclosureSEC source: 0001104659-24-010796 · tm245251-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,122 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-010796 · tm245251-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 26, 2023 Filed Jul 29, 2023 01:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-085497 · tm2322368-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 3,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of July 26, 2022, July 26, 2023, July 26, 2024 and July 26, 2025. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of July 26, 2022, July 26, 2023, July 26, 2024 and July 26, 2025. The restricted stock units have no expiration date. Read SEC document |
| July 26, 2023 Filed Jul 29, 2023 01:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 930 | $17.64 | $16,405.20 |
DisclosureSEC source: 0001104659-23-085497 · tm2322368-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,418 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction dated July 24, 2021 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| July 26, 2023 Filed Jul 29, 2023 01:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-085497 · tm2322368-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 81 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2023. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-019818 · tm236605-2_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,031 Underlying: Common Stock · 2,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 834 | $27.66 | $23,068.44 |
DisclosureSEC source: 0001104659-23-019818 · tm236605-2_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,151 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-019818 · tm236605-2_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 2,417 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2022 and August 31, 2022. Read SEC document |
| February 09, 2023 Filed Feb 15, 2023 00:30 UTC Amendment | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 843 | $27.51 | $23,190.93 |
DisclosureSEC source: 0001104659-23-022073 · tm236871-6_4aseq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,142 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:07 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 26,800 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-23-010485 · tm235340-2_4seq1.xml · derivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 Underlying: Common Stock · 26,800 shares Expires 2033-01-31 F3 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:07 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 10,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010485 · tm235340-2_4seq1.xml · derivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,493 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001104659-22-093714 · tm2224302-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,507 Underlying: Common Stock · 13,493 shares Expires 2031-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on July 26, 2021. 25% of the shares subject to the option vest and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 13,493 | $24.83 | $335,031.19 |
DisclosureSEC source: 0001104659-22-093714 · tm2224302-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,224 F1 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $24.79 to $24.86. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 13,493 | $19.02 | $256,636.86 |
DisclosureSEC source: 0001104659-22-093714 · tm2224302-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2022 Filed Jul 28, 2022 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 901 | $11.68 | $10,523.68 |
DisclosureSEC source: 0001104659-22-083680 · tm2222030-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,224 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.